The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

The present invention relates, in its broadest aspects, to steroidal glycosides useful in the treatment of skin disorders. Particularly, the invention relates to the use of certain steroidal glucosides, per se, or in the form aglycona, derivatives of spirostanol, of its precursor furastanol, or mixtures thereof, used in the treatment of skin disorders, for instance, psoriasis. The invention further relates to formulations containing steroidal glycosides, the process of obtaining extract from the Furcraea foetida plant, and a method of treating skin disorders.

A method of ameliorating symptoms of uremia includes administering a therapeutic agent including beraprost or each isomer constituting beraprost, or a salt thereof as an effective ingredient to an animal belonging to the Family Canidae, wherein an effective dosage is a dosage that does not significantly lower blood pressure.

The present invention relates to the field of skin rejuvenation. Specifically, the present invention provides compositions and methods for promoting skin rejuvenation using a toll-like receptor 3 (TLR3) agonist and retinoic acid or derivatives thereof. In a specific embodiment, a method for treating wrinkles in a subject comprises the steps of (a) administering to the area of the subject comprising a wrinkle a composition comprising an effective amount of retinoic acid or a derivative thereof; and administering to the area of the subject comprising a wrinkle a composition comprising an effective amount of a TLR3 agonist.

The present invention relates to the field of skin rejuvenation. Specifically, the present invention provides compositions and methods for promoting skin rejuvenation using a toll-like receptor 3 (TLR3) agonist and retinoic acid or derivatives thereof. In a specific embodiment, a method for treating wrinkles in a subject comprises the steps of (a) administering to the area of the subject comprising a wrinkle a composition comprising an effective amount of retinoic acid or a derivative thereof; and administering to the area of the subject comprising a wrinkle a composition comprising an effective amount of a TLR3 agonist.

The present invention relates to the field of pulmonary arterial hypertension. More specifically, the present invention provides methods and compositions useful in assessing Insulin-Like Growth Factor (IGF) axis proteins. In one embodiment, a method comprises the steps of (a) detecting an increased level of IGFBP2 relative to a control in a sample obtained from a subject suspected of having PAH; and (b) treating the subject with a PAH therapy.

The present invention relates to the field of pulmonary arterial hypertension. More specifically, the present invention provides methods and compositions useful in assessing Insulin-Like Growth Factor (IGF) axis proteins. In one embodiment, a method comprises the steps of (a) detecting an increased level of IGFBP2 relative to a control in a sample obtained from a subject suspected of having PAH; and (b) treating the subject with a PAH therapy.

The present invention relates to an injectable pre-formulation comprising: a) at least one of a mono-, di-, or tri-acyl lipid and/or a tocopherol; b) optionally at least one phospholipid; c) at least one biocompatible, organic solvent; and d) at least one prostacyclin analogue or a salt thereof; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynard's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.